NYSE:PLX
Protalix BioTherapeutics Inc Stock News
$1.15
+0.0200 (+1.77%)
At Close: Apr 19, 2024
Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2020 Results - Earnings Call Transcript
11:39am, Tuesday, 30'th Mar 2021
Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2020 Results - Earnings Call Transcript
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
06:50am, Tuesday, 30'th Mar 2021
CARMIEL, Israel, March 30, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercializatio
Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
06:50am, Monday, 22'nd Mar 2021
CARMIEL, Israel, March 22, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercializatio
Protalix's PRX–102 Monthly Treatment Shows Benefit In Fabry Disease
08:04am, Tuesday, 23'rd Feb 2021
Protalix BioTherapeutics Inc (NYSE: PLX) and its collaborating partner Chiesi Farmaceutici S.p.A. announced positive topline results from the BRIGHT Phase 3 trial evaluating pegunigalsidase al
Protalix BioTherapeutics Raises $35M Via Equity At 21% Discount
05:54am, Friday, 12'th Feb 2021
Protalix BioTherapeutics Inc (NYSE: PLX) prices the previously announced underwritten public offering of 7.6 million shares at $4.60 per share, a discount of around 21% on the last close of $5.79
Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions
07:47am, Thursday, 11'th Feb 2021
Protalix BioTherapeutics Inc (NYSE: PLX) has announced an exclusive worldwide license agreement with SarcoMed USA Inc for alidornase alfa, also known as PRX–110, for use in the treatment of any
CARMIEL, Israel, and BOSTON, Feb. 10, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and comme
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
06:50am, Wednesday, 30'th Dec 2020
CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization
CARMIEL, Israel and BOSTON, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commerci
FDA Decision For Protalix Postponed Due To Covid, But Fundamentals Remain Strong
08:23am, Monday, 28'th Dec 2020
Protalix had a PDUFA date for Fabry Disease drug PRX-102 on January 27, now postponed to April 27. The postponement seems only procedural and strictly Covid related, as the accelerated approval timeli
CARMIEL, Israel, Nov. 27, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization
